| Asthma
Advair Diskus vs Breo Ellipta
Side-by-side clinical, coverage, and cost comparison for asthma.Deep comparison between: Advair vs Breo Ellipta with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsBreo Ellipta has a higher rate of injection site reactions vs Advair based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Breo Ellipta but not Advair, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Advair
Breo Ellipta
At A Glance
Oral inhalation
Twice daily
ICS/LABA combination
Oral inhalation
Once daily
ICS/LABA combination
Indications
- Asthma
- Chronic Obstructive Airway Disease
- Chronic Obstructive Airway Disease
- Asthma
Dosing
Asthma 1 inhalation twice daily approximately 12 hours apart; adults and adolescents aged >=12 years may use 100/50, 250/50, or 500/50 strengths (max ADVAIR DISKUS 500/50 twice daily); pediatric patients aged 4 to 11 years use 1 inhalation of ADVAIR DISKUS 100/50 twice daily.
Chronic Obstructive Airway Disease 1 inhalation of ADVAIR DISKUS 250/50 twice daily approximately 12 hours apart.
Chronic Obstructive Airway Disease 1 actuation of BREO ELLIPTA 100/25 mcg once daily by oral inhalation; use a short-acting beta2-agonist for breakthrough symptoms between doses.
Asthma Adults >=18 years: 1 actuation of BREO ELLIPTA 100/25 mcg or 200/25 mcg once daily by oral inhalation; pediatric patients 12-17 years: 1 actuation of BREO ELLIPTA 100/25 mcg once daily; pediatric patients 5-11 years: 1 actuation of BREO ELLIPTA 50/25 mcg once daily; maximum dose is 1 inhalation of BREO ELLIPTA 200/25 mcg once daily.
Contraindications
- Primary treatment of status asthmaticus or other acute episodes of asthma or COPD where intensive measures are required
- Severe hypersensitivity to milk proteins or demonstrated hypersensitivity to fluticasone propionate, salmeterol, or any of the excipients
- Primary treatment of status asthmaticus or other acute episodes of COPD or asthma where intensive measures are required
- Severe hypersensitivity to milk proteins or demonstrated hypersensitivity to fluticasone furoate, vilanterol, or any excipient
Adverse Reactions
Most common (>=3%) Upper respiratory tract infection, pharyngitis, headaches, candidiasis mouth/throat, throat irritation, hoarseness/dysphonia, musculoskeletal pain, viral respiratory infections, nausea and vomiting, bronchitis, sinusitis, dizziness, muscle cramps and spasms
Serious Serious asthma-related events (hospitalizations, intubations, death), pneumonia in patients with COPD, cardiovascular and CNS effects, Candida albicans infection, immunosuppression, hypercorticism and adrenal suppression, reduction in bone mineral density, growth effects in pediatric patients, glaucoma and cataracts
Postmarketing Arrhythmias (including atrial fibrillation, supraventricular tachycardia, ventricular tachycardia), Cushing's syndrome, glaucoma, hyperglycemia, osteoporosis, paradoxical bronchospasm, immediate and delayed hypersensitivity reactions including anaphylaxis, agitation, depression, dysmenorrhea
Most common (>=3%) nasopharyngitis, upper respiratory tract infection, oropharyngeal candidiasis, headache, back pain, pneumonia, bronchitis, sinusitis, cough, arthralgia, influenza, pharyngitis, pyrexia
Serious serious asthma-related events (hospitalizations, intubations, death), oropharyngeal candidiasis, pneumonia, immunosuppression, hypercorticism, adrenal suppression, paradoxical bronchospasm, cardiovascular effects, reduction in bone mineral density, growth effects, glaucoma, cataracts
Postmarketing palpitations, tachycardia, hypersensitivity reactions (anaphylaxis, angioedema, rash, urticaria), hyperglycemia, muscle spasms, tremor, nervousness, paradoxical bronchospasm
Pharmacology
ADVAIR DISKUS combines fluticasone propionate, a synthetic trifluorinated corticosteroid that suppresses airway inflammation by acting on multiple cell types and mediators, and salmeterol, a selective long-acting beta2-adrenergic agonist (LABA) that relaxes bronchial smooth muscle by stimulating intracellular adenyl cyclase, increasing cyclic AMP levels.
Breo Ellipta combines fluticasone furoate, a synthetic trifluorinated ICS that inhibits inflammation via glucocorticoid receptor activation, with vilanterol, a LABA that relaxes bronchial smooth muscle by stimulating beta2-adrenergic receptors and increasing intracellular cyclic AMP.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Advair
- Covered on 5 commercial plans
- PA (9/12) · Step Therapy (5/12) · Qty limit (10/12)
Breo Ellipta
- Covered on 5 commercial plans
- PA (3/12) · Step Therapy (0/12) · Qty limit (10/12)
UnitedHealthcare
Advair
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Breo Ellipta
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Humana
Advair
- Covered on 0 commercial plans
- PA (2/3) · Step Therapy (2/3) · Qty limit (3/3)
Breo Ellipta
- Covered on 0 commercial plans
- PA (1/3) · Step Therapy (0/3) · Qty limit (1/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
No savings programs available for Advair.
No savings programs available for Breo Ellipta.
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
AdvairView full Advair profile
Breo ElliptaView full Breo Ellipta profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.